CytoMed Therapeutics (GDTC) Current Assets (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Current Assets of $2.8 million for Q4 2025, down 30.78% sequentially from $4.1 million in Q2 2025, and down 37.35% YoY from $4.5 million in Q4 2024.
CytoMed Therapeutics (GDTC) Current Assets (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Current Assets for 5 years, with the latest figure at $2.8 million in Q4 2025.
- Quarterly Current Assets fell 37.35% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (down 37.35% YoY) and the FY2025 annual result came in at $2.8 million, down 36.59% from the prior year.
- Current Assets fell to $2.8 million in Q4 2025 per GDTC's latest filing, from $4.1 million in the prior quarter.
- Over five years, Current Assets peaked at $11.5 million in Q2 2023 and troughed at $1.8 million in Q4 2022.
- A 5-year average of $5.3 million and a median of $4.3 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets soared 316.17% in 2023, then slumped 47.02% in 2025.
- Over 5 years, Current Assets stood at $2.4 million in 2021, then dropped by 25.69% to $1.8 million in 2022, then surged by 316.17% to $7.5 million in 2023, then tumbled by 39.68% to $4.5 million in 2024, then plunged by 37.35% to $2.8 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $2.8 million, $4.1 million, and $4.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - | 2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.83 Mn |
| Jun 30, 2025 | 4.08 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Jun 30, 2024 | 7.71 Mn |
| Dec 31, 2023 | 7.48 Mn |
| Jun 30, 2023 | 11.47 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 2.42 Mn |